» Articles » PMID: 26206625

Round Robin Test on Quantification of Amyloid-β 1-42 in Cerebrospinal Fluid by Mass Spectrometry

Overview
Specialties Neurology
Psychiatry
Date 2015 Jul 25
PMID 26206625
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Cerebrospinal fluid (CSF) amyloid-β 1-42 (Aβ42) is an important biomarker for Alzheimer's disease, both in diagnostics and to monitor disease-modifying therapies. However, there is a great need for standardization of methods used for quantification. To overcome problems associated with immunoassays, liquid chromatography-tandem mass spectrometry (LC-MS/MS) has emerged as a critical orthogonal alternative.

Methods: We compared results for CSF Aβ42 quantification in a round robin study performed in four laboratories using similar sample preparation methods and LC-MS instrumentation.

Results: The LC-MS results showed excellent correlation between laboratories (r(2) >0.98), high analytical precision, and good correlation with enzyme-linked immunosorbent assay (r(2) >0.85). The use of a common reference sample further decreased interlaboratory variation.

Discussion: Our results indicate that LC-MS is suitable for absolute quantification of Aβ42 in CSF and highlight the importance of developing a certified reference material.

Citing Articles

Cerebrospinal and Blood Biomarkers in Alzheimer's Disease: Did Mild Cognitive Impairment Definition Affect Their Clinical Usefulness?.

Bivona G, Iemmolo M, Ghersi G Int J Mol Sci. 2023; 24(23).

PMID: 38069230 PMC: 10706963. DOI: 10.3390/ijms242316908.


Alzheimer Disease Biomarkers: Moving from CSF to Plasma for Reliable Detection of Amyloid and tau Pathology.

Kang J, Korecka M, Lee E, Cousins K, Tropea T, Chen-Plotkin A Clin Chem. 2023; 69(11):1247-1259.

PMID: 37725909 PMC: 10895336. DOI: 10.1093/clinchem/hvad139.


Harmonization and standardization of biofluid-based biomarker measurements for AT(N) classification in Alzheimer's disease.

Giangrande C, Delatour V, Andreasson U, Blennow K, Gobom J, Zetterberg H Alzheimers Dement (Amst). 2023; 15(3):e12465.

PMID: 37600860 PMC: 10432775. DOI: 10.1002/dad2.12465.


Biofluid Biomarkers of Alzheimer's Disease: Progress, Problems, and Perspectives.

Huang S, Wang Y, Guo J Neurosci Bull. 2022; 38(6):677-691.

PMID: 35306613 PMC: 9206048. DOI: 10.1007/s12264-022-00836-7.


Mass spectrometry-based methods for robust measurement of Alzheimer's disease biomarkers in biological fluids.

Korecka M, Shaw L J Neurochem. 2021; 159(2):211-233.

PMID: 34244999 PMC: 9057379. DOI: 10.1111/jnc.15465.